Wells Fargo & Company MN lowered its holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 74.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 27,506 shares of the company's stock after selling 81,454 shares during the period. Wells Fargo & Company MN's holdings in GoodRx were worth $128,000 at the end of the most recent reporting period.
A number of other large investors have also recently modified their holdings of GDRX. Barclays PLC raised its position in GoodRx by 1,316.1% during the third quarter. Barclays PLC now owns 140,113 shares of the company's stock valued at $973,000 after purchasing an additional 130,219 shares in the last quarter. Franklin Resources Inc. purchased a new position in shares of GoodRx in the 3rd quarter worth about $5,675,000. JPMorgan Chase & Co. increased its position in shares of GoodRx by 358.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,293 shares of the company's stock valued at $169,000 after purchasing an additional 18,997 shares during the last quarter. Sugar Maple Asset Management LLC purchased a new position in shares of GoodRx during the 4th quarter valued at about $122,000. Finally, Gagnon Securities LLC lifted its position in GoodRx by 9.9% in the 4th quarter. Gagnon Securities LLC now owns 69,867 shares of the company's stock worth $325,000 after buying an additional 6,266 shares during the last quarter. Institutional investors own 63.77% of the company's stock.
Wall Street Analyst Weigh In
GDRX has been the topic of several research reports. Truist Financial decreased their price target on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a research note on Thursday, April 10th. UBS Group reduced their price objective on GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a research note on Tuesday. Wells Fargo & Company lowered their target price on GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. Finally, The Goldman Sachs Group dropped their target price on GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Five research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $7.33.
Check Out Our Latest Stock Report on GoodRx
GoodRx Stock Down 0.7%
GDRX traded down $0.03 during trading on Wednesday, reaching $4.27. The stock had a trading volume of 748,612 shares, compared to its average volume of 1,414,482. The stock's 50 day moving average is $4.48 and its two-hundred day moving average is $4.71. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of -142.33, a P/E/G ratio of 2.46 and a beta of 1.24. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx Holdings, Inc. has a one year low of $3.68 and a one year high of $9.26.
GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.09 earnings per share for the quarter, topping analysts' consensus estimates of $0.04 by $0.05. GoodRx had a negative net margin of 2.05% and a positive return on equity of 5.35%. The company had revenue of $202.97 million during the quarter, compared to analyst estimates of $202.25 million. During the same period in the previous year, the business earned $0.08 EPS. The firm's revenue for the quarter was up 2.6% on a year-over-year basis. As a group, analysts expect that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.
GoodRx Company Profile
(
Free Report)
GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Read More
Before you consider GoodRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.
While GoodRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
